SMARCB1 and rhabdoid tumor: The diagnosis of primary rhabdoid tumors of the liver is currently based on their histopathology in association with their characteristic underlying biology and requires testing for loss of SMARCB1 expression according to the current classification, which was not available at the time these patients were enrolled in the trial [10].